# Camzyos® (mavacamten) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mavacamten

> The FDA approved Camzyos® (mavacamten), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on April 28, 2022 for to treat certain classes of obstructive hypertrophic cardiomyopathy.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Camzyos® (mavacamten) FDA approved?

Yes. The FDA approved Camzyos® (mavacamten), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on April 28, 2022 for to treat certain classes of obstructive hypertrophic cardiomyopathy. FDA novel drug approvals: "Camzyos | mavacamten | 4/28/2022 | To treat certain classes of obstructive hypertrophic cardiomyopathyDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/mavacamten)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/mavacamten#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Camzyos® (mavacamten) |
| Codes | MYK461, MYK-461, BMS-986427 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | To treat certain classes of obstructive hypertrophic cardiomyopathy, [Hypertrophic Cardiomyopathy](https://sec-api.dev/indications/hypertrophic-cardiomyopathy), Cardiomyopathy, Hypertrophic |
| Modality |  |
| FDA designations | priority review |

## Timeline

### April 28, 2022: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat certain classes of obstructive hypertrophic cardiomyopathy.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Camzyos | mavacamten | 4/28/2022 | To treat certain classes of obstructive hypertrophic cardiomyopathyDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022
- openFDA Drugs@FDA: "NDA214998 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20220428, review_priority STANDARD; sponsor_name BRISTOL; product CAMZYOS (MAVACAMTEN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214998%22

### June 15, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214998 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20230615, review_priority STANDARD; sponsor_name BRISTOL; product CAMZYOS (MAVACAMTEN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214998%22

### April 17, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214998 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20250417, review_priority STANDARD; sponsor_name BRISTOL; product CAMZYOS (MAVACAMTEN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214998%22

### November 25, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Cardiomyopathy, Hypertrophic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06253221 (A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06253221

### January 16, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2/3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03723655 (A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-01-16 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT03723655

### September 30, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214998 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20260930, review_priority PRIORITY; sponsor_name BRISTOL; product CAMZYOS (MAVACAMTEN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214998%22

## Same indication

- [EDG-7500](https://sec-api.dev/pdufa/edg-7500) (EWTX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mavacamten.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Camzyos® (mavacamten) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mavacamten

```bibtex
@misc{secapidev_pdufa_mavacamten_20261116,
  title        = {Camzyos® (mavacamten) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mavacamten}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mavacamten_20261116","title":"Camzyos® (mavacamten) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mavacamten","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
